Literature DB >> 10875754

Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system.

A Sugiyama1, N N Aye, Y Yatomi, Y Ozaki, K Hashimoto.   

Abstract

Recent studies have indicated that sphingosine 1-phosphate (Sph-1-P) is released into the blood flow from activated platelets upon stimulation to exhibit a wide spectrum of biological functions. The purpose of the present study was to assess the acute cardiovascular effects of circulating Sph-1-P in the in vivo rat model. Intravenous administration of Sph-1-P decreased the heart rate, ventricular contraction and blood pressure, while it hardly affected the atrioventricular and intraventricular conduction. Sph-1-P did not affect the adenylate cyclase activities of the membrane preparations made from the right atrium and left ventricle. These results suggest that functional receptors like lysophospholipid receptor Edg-1, which can inhibit adenylate cyclase via Gi protein, are lacking in the rat heart. Moreover, these observations will provide a clue to better understand the various types of Sph-1-P-related pathophysiological processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10875754     DOI: 10.1254/jjp.82.338

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  9 in total

1.  Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats.

Authors:  A Bischoff; D Meyer Zu Heringdorf; K H Jakobs; M C Michel
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  S1P Signaling and De Novo Biosynthesis in Blood Pressure Homeostasis.

Authors:  Anna Cantalupo; Annarita Di Lorenzo
Journal:  J Pharmacol Exp Ther       Date:  2016-06-17       Impact factor: 4.030

3.  Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors.

Authors:  K Liliom; G Sun; M Bünemann; T Virág; N Nusser; D L Baker; D A Wang; M J Fabian; B Brandts; K Bender; A Eickel; K U Malik; D D Miller; D M Desiderio; G Tigyi; L Pott
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

Review 4.  Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites.

Authors:  Astrid E Alewijnse; Stephan L M Peters; Martin C Michel
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.

Authors:  Yugesh Kharel; Thomas P Mathews; Amanda M Gellett; Jose L Tomsig; Perry C Kennedy; Morgan L Moyer; Timothy L Macdonald; Kevin R Lynch
Journal:  Biochem J       Date:  2011-12-15       Impact factor: 3.857

Review 6.  Implication of sphingosin-1-phosphate in cardiovascular regulation.

Authors:  Ningjun Li; Fan Zhang
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

Review 7.  Sphingosine-1-phosphate receptor signalling in the heart.

Authors:  Christopher K Means; Joan Heller Brown
Journal:  Cardiovasc Res       Date:  2009-03-12       Impact factor: 10.787

8.  I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Authors:  Yaron D Barac; Orit Bar-Am; Esti Liani; Tamar Amit; Luba Frolov; Elena Ovcharenko; Itzchak Angel; Moussa B H Youdim; Ofer Binah
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.

Authors:  Ryan M Fryer; Akalushi Muthukumarana; Paul C Harrison; Suzanne Nodop Mazurek; Rong Rhonda Chen; Kyle E Harrington; Roger M Dinallo; Joshua C Horan; Lori Patnaude; Louise K Modis; Glenn A Reinhart
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.